On Friday morning, President Trump received an experimental treatment for Covid-19 developed by Regeneron. At the time, it had only been provided to fewer than 10 patients outside of clinical trials, under so-called compassionate use. Data for the drug had been presented for the first time earlier that week on a company conference call.
It was, to put it mildly, an unusual situation.
About the Author Reprints
